Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
Gerhard Jorch(Zentrum für Kinderheilkunde), Robert P. Wise(Center for Biologics Evaluation and Research), Bernard Hoet(GlaxoSmithKline (Belgium)), Martin Schlaud(Robert Koch Institute), Ulrich Heininger(University Children’s Hospital Basel), Jan Bonhoeffer(University Children’s Hospital Basel), Edwin Lewis(Kaiser Permanente), Synne Sandbu(Norwegian Institute of Public Health), Thea Kølsen Fischer, Katrin Kohl(Centers for Disease Control and Prevention), Ann Rebecca Grossbart Schwartz(United States Food and Drug Administration), Frederick Varricchio(Rutgers, The State University of New Jersey), E. Anthony S. Nelson(Chinese University of Hong Kong), Christiane Meyer(Robert Koch Institute), Terhi Tapiainen(Baylor College of Medicine)
Cited by 43
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis
|The Journal of Infectious Diseases|2019|534
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
|The Pediatric Infectious Disease Journal|2004|381